<DOC>
	<DOCNO>NCT02003144</DOCNO>
	<brief_summary>The purpose study determine whether eculizumab long-term use safe effective patient relapse NMO .</brief_summary>
	<brief_title>An Open Label Extension Trial Eculizumab Relapsing NMO Patients</brief_title>
	<detailed_description>This study open label extension study confirm long term safety efficacy eculizumab subject relapse NMO complete initial double-blind , randomize , placebo-controlled trial ECU-NMO-301 .</detailed_description>
	<mesh_term>Neuromyelitis Optica</mesh_term>
	<criteria>Key 1 . Patient complete ECUNMO301 trial 2 . Patient give write informed consent Key 1 . Patients withdraw ECUNMO301 trial result AE related trial drug 2 . Female patient pregnant , breastfeeding , intend conceive course trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Long-term safety study</keyword>
	<keyword>Extension trial</keyword>
	<keyword>Eculizumab</keyword>
	<keyword>Neuromyelitis Optica Spectrum Disorder</keyword>
	<keyword>Devic 's disease</keyword>
	<keyword>Transverse Myelitis</keyword>
	<keyword>Optic Neuritis</keyword>
	<keyword>Relapse</keyword>
	<keyword>NMO-IgG</keyword>
	<keyword>CNS Autoimmune Disorders</keyword>
	<keyword>Demyelinating Disorders</keyword>
</DOC>